1-9 of 9
Paul A. Clarke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A143: Coupling fragment-based screening with targeted protein degradation and genetic rescue to identify and explore the function of a non-canonical pocket on eIF4E

Swee Y Sharp, Marianna Martella, Christopher I Milton, George Ward, Mladen Vinkovic, Caroline Richardson, Andrew Woodhead, Paul A Clarke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A143.
https://doi.org/10.1158/1535-7163.TARG-23-A143
Published: 01 December 2023
View article titled, Abstract A143: Coupling fragment-based screening with targeted protein degradation and genetic rescue to identify and explore the function of a non-canonical pocket on eIF4E
Journal Articles

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer

Charlotte K. Milton, Annette J. Self, Paul A. Clarke, Udai Banerji, Federica Piccioni, David E. Root, Steven R. Whittaker
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (7): 1423–1435.
https://doi.org/10.1158/1535-7163.MCT-19-1131
Published: 02 July 2020
View article titled, A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer
Open the PDF for A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A187: Exploring isoform-dependent functions of the mediator kinases in colorectal cancer

Olajumoke O. Popoola, Maria J. Ortiz-Ruiz, Konstantinos Mitsopoulos, Aurelie Mallinger, Robert Te-Poele, Kai Schiemann, Paul Workman, Dirk Wienke, Julian Blagg, Suzanne A. Eccles, Paul A. Clarke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A187.
https://doi.org/10.1158/1535-7163.TARG-17-A187
Published: 01 January 2018
View article titled, Abstract A187: Exploring isoform-dependent functions of the mediator kinases in colorectal cancer
Journal Articles

Abstract PR02: Identification of a potent and selective chemical probe for exploring the role of CDK8/19 in cancer biology

Paul A. Clarke, Trevor Dale, Christina Esdar, Dennis Waalboer, Olajumoke Adeniji-Popoola, Maria-Jesus Ortiz-Ruiz, Aurelie Mallinger, Ken Ewan, Robert te Poele, Sharon Gowan, Paul Workman, Kai Schiemann, Suzanne A. Eccles, Dirk Wienke, Julian Blagg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): PR02.
https://doi.org/10.1158/1535-7163.TARG-15-PR02
Published: 01 December 2015
View article titled, Abstract PR02: Identification of a potent and selective chemical probe for exploring the role of CDK8/19 in cancer biology
Journal Articles

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Craig P. Carden, Adam Stewart, Parames Thavasu, Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B Kaye, Udai Banerji
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1609–1617.
https://doi.org/10.1158/1535-7163.MCT-11-0996
Published: 05 July 2012
View article titled, The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Open the PDF for The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract C7: Sensitization of human colorectal cancer cells to TRAIL induced‐apoptosis following inhibition of PI3K or HSP90

Grazia Saturno, Paul A. Clarke, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C7.
https://doi.org/10.1158/1535-7163.TARG-09-C7
Published: 10 December 2009
View article titled, Abstract C7: Sensitization of human colorectal cancer cells to TRAIL induced‐apoptosis following inhibition of PI3K or HSP90
Journal Articles

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I. Raynaud, Suzanne A. Eccles, Sonal Patel, Sonia Alix, Gary Box, Irina Chuckowree, Adrian Folkes, Sharon Gowan, Alexis De Haven Brandon, Francesca Di Stefano, Angela Hayes, Alan T. Henley, Letitia Lensun, Giles Pergl-Wilson, Anthony Robson, Nahid Saghir, Alexander Zhyvoloup, Edward McDonald, Peter Sheldrake, Stephen Shuttleworth, Melanie Valenti, Nan Chi Wan, Paul A. Clarke, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1725–1738.
https://doi.org/10.1158/1535-7163.MCT-08-1200
Published: 14 July 2009
View article titled, Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Open the PDF for Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 in another window
Includes: Supplementary data
Journal Articles

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Richard D. Baird, Jos Kitzen, Paul A. Clarke, Andre Planting, Sarah Reade, Alison Reid, Lyndsey Welsh, Luis López Lázaro, Begona de las Heras, Ian R. Judson, Stan B. Kaye, Ferry Eskens, Paul Workman, Johann S. deBono, Jaap Verweij
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (6): 1430–1437.
https://doi.org/10.1158/1535-7163.MCT-08-1167
Published: 10 June 2009
View article titled, Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Open the PDF for Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors in another window
Includes: Supplementary data
Journal Articles

Inhibition of Kirsten-ras Expression in Human Colorectal Cancer Using Rationally Selected Kirsten-ras Antisense Oligonucleotides

Paul J. Ross, Mark George, David Cunningham, Francesca DiStefano, H. Jervoise N. Andreyev, Paul Workman, Paul A. Clarke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2001) 1 (1): 29–41.
Published: 01 November 2001
View article titled, Inhibition of <em>Kirsten-ras</em> Expression in Human Colorectal Cancer Using Rationally Selected <em>Kirsten-ras</em> Antisense Oligonucleotides
Open the PDF for Inhibition of <em>Kirsten-ras</em> Expression in Human Colorectal Cancer Using Rationally Selected <em>Kirsten-ras</em> Antisense Oligonucleotides in another window